Chemours Deferred Long Term Liab vs Net Working Capital Analysis
CC Stock | USD 27.32 0.29 1.07% |
Chemours financial indicator trend analysis is way more than just evaluating Chemours prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Chemours is a good investment. Please check the relationship between Chemours Deferred Long Term Liab and its Net Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemours Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Deferred Long Term Liab vs Net Working Capital
Deferred Long Term Liab vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Chemours Deferred Long Term Liab account and Net Working Capital. At this time, the significance of the direction appears to have strong relationship.
The correlation between Chemours' Deferred Long Term Liab and Net Working Capital is 0.74. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Chemours Co, assuming nothing else is changed. The correlation between historical values of Chemours' Deferred Long Term Liab and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Chemours Co are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Deferred Long Term Liab i.e., Chemours' Deferred Long Term Liab and Net Working Capital go up and down completely randomly.
Correlation Coefficient | 0.74 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Net Working Capital
Most indicators from Chemours' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Chemours current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemours Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. At present, Chemours' Enterprise Value Multiple is projected to increase significantly based on the last few years of reporting.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.4B | 1.6B | 1.3B | 1.2B | Total Revenue | 6.3B | 6.8B | 6.0B | 5.1B |
Chemours fundamental ratios Correlations
Click cells to compare fundamentals
Chemours Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Chemours fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 164.8M | 166.3M | 168.7M | 158.3M | 148.9M | 140.1M | |
Total Assets | 7.3B | 7.1B | 7.6B | 7.6B | 8.3B | 7.5B | |
Other Current Liab | 477M | 537M | 668M | 554M | 1.2B | 1.3B | |
Total Current Liabilities | 1.5B | 1.4B | 1.9B | 1.9B | 2.5B | 1.8B | |
Total Stockholder Equity | 689M | 813M | 1.1B | 1.1B | 737M | 1.1B | |
Other Liab | 751M | 626M | 707M | 854M | 982.1M | 711.9M | |
Property Plant And Equipment Net | 3.9B | 3.7B | 3.4B | 3.4B | 3.5B | 3.6B | |
Accounts Payable | 923M | 820M | 1.2B | 1.3B | 1.1B | 1.1B | |
Non Current Assets Total | 4.5B | 4.4B | 4.2B | 4.4B | 4.4B | 4.4B | |
Non Currrent Assets Other | 391M | 252M | 310M | 573M | 374M | 416.1M | |
Other Assets | 292M | 405M | 547M | 725M | 833.8M | 424.1M | |
Long Term Debt | 4.0B | 4.0B | 3.7B | 3.6B | 4.0B | 3.2B | |
Net Receivables | 674M | 511M | 720M | 626M | 610M | 602.4M | |
Liabilities And Stockholders Equity | 7.3B | 7.1B | 7.6B | 7.6B | 8.3B | 7.5B | |
Non Current Liabilities Total | 5.0B | 4.8B | 4.6B | 4.6B | 5.0B | 4.1B | |
Inventory | 1.1B | 939M | 1.1B | 1.4B | 1.4B | 1.2B | |
Other Current Assets | 81M | 78M | 75M | 82M | 66M | 64.8M | |
Other Stockholder Equity | (213M) | (182M) | (303M) | (722M) | (773M) | (734.4M) | |
Total Liab | 6.6B | 6.3B | 6.5B | 6.5B | 7.5B | 6.0B | |
Property Plant And Equipment Gross | 3.9B | 3.7B | 9.2B | 9.4B | 9.6B | 5.2B | |
Total Current Assets | 2.8B | 2.6B | 3.3B | 3.2B | 3.8B | 3.0B | |
Accumulated Other Comprehensive Income | (349M) | (310M) | (364M) | (343M) | (274M) | (287.7M) | |
Short Term Debt | 13M | 134M | 78M | 25M | 106M | 86.1M | |
Intangible Assets | 28M | 21M | 14M | 6M | 3M | 2.9M | |
Property Plant Equipment | 3.9B | 3.5B | 3.4B | 3.2B | 3.6B | 3.5B | |
Net Tangible Assets | 515M | 646M | 973M | 992M | 892.8M | 710.5M | |
Retained Earnings | 1.2B | 1.3B | 1.7B | 2.2B | 1.8B | 1.1B | |
Cash | 943M | 1.1B | 1.5B | 1.1B | 1.8B | 1.2B | |
Deferred Long Term Liab | 148M | 36M | 49M | 61M | 54.9M | 96.1M | |
Long Term Investments | 162M | 167M | 169M | 175M | 158M | 171.6M | |
Short Long Term Debt | 13M | 134M | 21M | 25M | 51M | 41.5M | |
Short Long Term Debt Total | 4.4B | 4.3B | 3.9B | 3.8B | 4.3B | 4.4B | |
Net Debt | 3.5B | 3.2B | 2.5B | 2.7B | 2.5B | 2.3B | |
Cash And Short Term Investments | 943M | 1.1B | 1.5B | 1.1B | 1.8B | 1.3B | |
Retained Earnings Total Equity | 1.2B | 1.3B | 1.7B | 2.2B | 2.5B | 2.6B | |
Long Term Debt Total | 4.0B | 4.0B | 3.7B | 3.6B | 3.2B | 3.1B | |
Capital Surpluse | 859M | 890M | 944M | 1.0B | 1.2B | 958.4M |
Pair Trading with Chemours
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chemours position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chemours will appreciate offsetting losses from the drop in the long position's value.Moving against Chemours Stock
0.56 | DNMR | Danimer Scientific Financial Report 8th of May 2024 | PairCorr |
0.56 | ECL | Ecolab Inc Earnings Call This Week | PairCorr |
0.55 | CMT | Core Molding Technologies Financial Report 14th of May 2024 | PairCorr |
0.52 | ASH | Ashland Global Holdings Earnings Call This Week | PairCorr |
0.46 | CBT | Cabot Financial Report 13th of May 2024 | PairCorr |
The ability to find closely correlated positions to Chemours could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chemours when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chemours - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chemours Co to buy it.
The correlation of Chemours is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chemours moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chemours moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Chemours can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemours Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Chemours information on this page should be used as a complementary analysis to other Chemours' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Chemours Stock analysis
When running Chemours' price analysis, check to measure Chemours' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemours is operating at the current time. Most of Chemours' value examination focuses on studying past and present price action to predict the probability of Chemours' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chemours' price. Additionally, you may evaluate how the addition of Chemours to your portfolios can decrease your overall portfolio volatility.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Chemours' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemours. If investors know Chemours will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemours listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.91) | Dividend Share 1 | Earnings Share (1.60) | Revenue Per Share 40.473 | Quarterly Revenue Growth 0.017 |
The market value of Chemours is measured differently than its book value, which is the value of Chemours that is recorded on the company's balance sheet. Investors also form their own opinion of Chemours' value that differs from its market value or its book value, called intrinsic value, which is Chemours' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemours' market value can be influenced by many factors that don't directly affect Chemours' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemours' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemours is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemours' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.